Nicotinamide supplement for glaucoma. Early studies show safety and potential benefits, but larger clinical trials are still underway. A phase 2 randomized controlled trial in the United States of 32 individuals with open-angle glaucoma found that oral supplementation with 3 g/day of nicotinamide and 3 g/day of calcium pyruvate for 9 weeks led to an . Jan 10, 2025 · After laboratory studies, 6,8–10,12,13 data from pilot human clinical studies have provided encouraging results for the role of nicotinamide in glaucoma neuroprotection. Jan 10, 2024 · Natural glaucoma treatment with vitamin B3 (nicotinamide), pyruvate, and vitamin B12 to prevent glaucoma blindness. Could this be the future of glaucoma Nov 18, 2021 · In this randomized, double-blind, placebo-controlled clinical trial, patients with manifest open-angle glaucoma treated with a combination of nutritional supplements (nicotinamide and pyruvate) experienced a statistically significant improvement in visual function based on the number of improving test locations on SAP compared with the placebo Apr 8, 2025 · Nicotinamide is a promising candidate for glaucoma neuroprotection, as it has been shown to improve mitochondrial health in glaucoma and other conditions. A world-first clinical trial led by the Centre for Eye Research Australia has shown that vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma. South Bay Retina | Nicotinamide, a form of vitamin B3, is emerging as a promising supplement for glaucoma. Nicotinamide, a naturally occurring diet-rich nutrient, has Apr 9, 2025 · Now researchers are asking: Could nicotinamide also help protect vision in people with glaucoma? But like all supplements, nicotinamide can have side effects and interact with other medications. Background: Glaucoma is a major cause of incurable ocular morbidity and poses significant challenges in its management due to the limited treatment options and potential adverse effects. Jul 17, 2024 · When choosing an eye health supplement, look for one containing nicotinamide to support retinal ganglion cell health and optic nerve function. Additionally, low retinal pyruvate levels are associated with dysregulated glucose metabolism in mouse models of glaucoma. Based on laboratory and human stu Dec 1, 2023 · I highlight the emerging role of PAD and derangement of axonal NAD homeostasis in glaucoma neuropathy. Oct 14, 2024 · Nicotinamide Nicotinamide (vitamin B3) has shown promise as a potential therapeutic approach for glaucoma. Recent studies suggest that nicotinamide may help protect RGCs by enhancing mitochondrial function, reducing oxidative stress, and supporting cell energy production. In addition, I discuss the therapeutic potential of NAD supplements in glaucoma neuroprotection and evaluate positive data from proof-of-concept clinical studies that prompted ongoing Phase 2/3 trials. Nutravision combines nicotinamide with other natural antioxidants such as bilberry, ginkgo biloba, and saffron to reduce free radical damage and promote healthy blood circulation, making it the most comprehensive glaucoma neuroprotection supplement This joint position paper from the American Academy of Ophthalmology and the American Glaucoma Society evaluates the use of nicotinamide for glaucoma neuroprotection. What Is Nicotinamide? Mar 4, 2025 · Article | 2025 American Glaucoma Society Meeting AGS Recommends Cautious Approach to Nicotinamide Although nicotinamide, an over-the-counter supplement, remains intriguing as a potential neuroprotective agent for glaucoma, more research is needed to verify its long-term safety at higher doses. While it doesn’t lower eye |pressure, research suggests it may protect the optic nerve by boosting cellular energy and supporting retinal ganglion cells. It has two arms: the Swedish Glaucoma Nicotinamide Trial and the vitamin B3 in glaucoma study. So it’s important to be aware of nicotinamide safety concerns and discuss them with your doctor. T rials to W atch O ut F or The Glaucoma Nicotinamide Trial is a prospective, randomized, placebo-controlled double-masked clinical trial that started in May 2022, with a projected end date of December 2026. accomhh vnopap kmn idxwhfs guk ivqxu vpvd ocwpis sokuog yqyit